Literature DB >> 21744043

Antifungal susceptibility and virulence attributes of bloodstream isolates of Candida from Hong Kong and Finland.

C J Seneviratne1, S S W Wong, K Y Yuen, J H Meurman, P Pärnänen, M Vaara, L P Samaranayake.   

Abstract

Candida bloodstream infection has dramatically increased in the last decade due to the growing number of immunocompromised populations worldwide. In this study, we evaluated the antifungal susceptibility profiles and virulence attributes of Candida bloodstream isolates (CBIs) derived from Hong Kong and Finland, information which are vital for devising empirical clinical strategies. Susceptibility testing of a wide range of antifungals including fluconazole, itraconazole, voriconazole, ketoconazole, 5-fluorocytosine, amphotericin B and caspofungin was performed. Haemolytic activity and secretion of proteinase of CBIs were also examined. All CBIs derived from Hong Kong were susceptible to all the antifungals tested whilst some CBIs from Finland were resistant to azoles and caspofungin. C. albicans, C. glabrata and C. tropicalis showed higher haemolytic activity whereas C. parapsilosis and C. guilliermondii were non-haemolytic in general. Proteinase activity of the Finland C. albicans isolates was significantly higher than the Hong Kong isolates. Our data provide a glimpse of the possible evolutionary changes in pathogenic potential of Candida that may be occurring in different regions of the world. Therefore, continuous surveillance and availability of local data should be taken into consideration when treating candidemia patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744043     DOI: 10.1007/s11046-011-9444-4

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  15 in total

1.  Species distribution and antifungal susceptibility of blood Candida isolates at a tertiary hospital in southern Taiwan, 1999-2006.

Authors:  Po-Lin Chen; Hsiu-Jung Lo; Chi-Jung Wu; Hsin-Chun Lee; Chia-Ming Chang; Nan-Yao Lee; An-Huei Wang; Wen-Liang Lin; Nai-Ying Ko; Ching-Chi Lee; Wen-Chien Ko
Journal:  Mycoses       Date:  2009-12-17       Impact factor: 4.377

2.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

3.  A first Portuguese epidemiological survey of fungaemia in a university hospital.

Authors:  S Costa-de-Oliveira; C Pina-Vaz; D Mendonça; A Gonçalves Rodrigues
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-01-19       Impact factor: 3.267

4.  Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility.

Authors:  M C Arendrup; K Fuursted; B Gahrn-Hansen; H C Schønheyder; J D Knudsen; I M Jensen; B Bruun; J J Christensen; H K Johansen
Journal:  Clin Microbiol Infect       Date:  2008-02-22       Impact factor: 8.067

5.  Microbial profile and drug resistance of Candida strains isolated from the blood of children: an 11-year study.

Authors:  Eugeniusz Małafiej; Anna Ciebiada Adamiec; Urszula Tworzyańska
Journal:  Mycoses       Date:  2008-06-21       Impact factor: 4.377

6.  Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms.

Authors:  C J Seneviratne; L J Jin; Y H Samaranayake; L P Samaranayake
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

7.  Epidemiology and outcome of Candida bloodstream infection in an intensive care unit in Hong Kong.

Authors:  H Y Yap; K M Kwok; Charles D Gomersall; S C Fung; T C Lam; P N Leung; Mamie Hui; Gavin M Joynt
Journal:  Hong Kong Med J       Date:  2009-08       Impact factor: 2.227

8.  Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data.

Authors:  George Samonis; Diamantis P Kofteridis; Emmanouil Saloustros; Konstantina P Giannopoulou; Fotinie Ntziora; Athanasia Christidou; Sofia Maraki; Matthew E Falagas
Journal:  Scand J Infect Dis       Date:  2008

9.  In-vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents.

Authors:  T Wu; L P Samaranayake; B Y Cao; J Wang
Journal:  J Med Microbiol       Date:  1996-04       Impact factor: 2.472

10.  Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea.

Authors:  Jin-Sol Lee; Jong Hee Shin; Kyungwon Lee; Mi-Na Kim; Bo-Moon Shin; Young Uh; Wee-Gyo Lee; Hye Soo Lee; Chulhun L Chang; Soo Hyun Kim; Myung Geun Shin; Soon Pal Suh; Dong Wook Ryang
Journal:  Yonsei Med J       Date:  2007-10-31       Impact factor: 2.759

View more
  10 in total

1.  Sub-inhibitory concentrations of antifungals suppress hemolysin activity of oral Candida albicans and Candida tropicalis isolates from HIV-infected individuals.

Authors:  Sukumaran Anil; Mohamed Hashem; Sajith Vellappally; Shankargouda Patil; H M H N Bandara; L P Samaranayake
Journal:  Mycopathologia       Date:  2014-08-21       Impact factor: 2.574

2.  Delicate Metabolic Control and Coordinated Stress Response Critically Determine Antifungal Tolerance of Candida albicans Biofilm Persisters.

Authors:  Peng Li; Chaminda J Seneviratne; Emanuele Alpi; Juan A Vizcaino; Lijian Jin
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

Review 3.  Candida parapsilosis and the neonate: epidemiology, virulence and host defense in a unique patient setting.

Authors:  Brian D W Chow; Jennifer R Linden; Joseph M Bliss
Journal:  Expert Rev Anti Infect Ther       Date:  2012-08       Impact factor: 5.091

4.  Editorial: Antifungal Drug Discovery: New Theories and New Therapies.

Authors:  Chaminda J Seneviratne; Edvaldo A R Rosa
Journal:  Front Microbiol       Date:  2016-05-23       Impact factor: 5.640

5.  Relationship between the Antifungal Susceptibility Profile and the Production of Virulence-Related Hydrolytic Enzymes in Brazilian Clinical Strains of Candida glabrata.

Authors:  Maria Helena Galdino Figueiredo-Carvalho; Lívia de Souza Ramos; Leonardo Silva Barbedo; Jean Carlos Almeida de Oliveira; André Luis Souza Dos Santos; Rodrigo Almeida-Paes; Rosely Maria Zancopé-Oliveira
Journal:  Mediators Inflamm       Date:  2017-07-26       Impact factor: 4.711

Review 6.  Potential Use of Phenolic Acids as Anti-Candida Agents: A Review.

Authors:  Guilherme R Teodoro; Kassapa Ellepola; Chaminda J Seneviratne; Cristiane Y Koga-Ito
Journal:  Front Microbiol       Date:  2015-12-21       Impact factor: 5.640

7.  Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011.

Authors:  Fang Li; Lin Wu; Bin Cao; Yuyu Zhang; Xiaoli Li; Yingmei Liu
Journal:  BMC Infect Dis       Date:  2013-07-30       Impact factor: 3.090

8.  In vitro and in vivo activity of a novel antifungal small molecule against Candida infections.

Authors:  Sarah Sze Wah Wong; Richard Yi Tsun Kao; Kwok Yong Yuen; Yu Wang; Dan Yang; Lakshman Perera Samaranayake; Chaminda Jayampath Seneviratne
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

9.  Antifungal Susceptibility in Serum and Virulence Determinants of Candida Bloodstream Isolates from Hong Kong.

Authors:  Chaminda J Seneviratne; Suhasini Rajan; Sarah S W Wong; Dominic N C Tsang; Christopher K C Lai; Lakshman P Samaranayake; Lijian Jin
Journal:  Front Microbiol       Date:  2016-02-26       Impact factor: 5.640

10.  Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity.

Authors:  Danillo F M C Veloso; Naiara I G M Benedetti; Renato I Ávila; Thiago S A Bastos; Thaísa C Silva; Maria R R Silva; Aline C Batista; Marize C Valadares; Eliana M Lima
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.